SCHEMBL6035533

SCHEMBL6035533

Cc1cccc(CC(=O)O)c1OCCCc1cn(-c2ccc(C(F)(F)F)cn2)nc1C1CCCCC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 3/20 0.37
GCGR P47871 1/20 0.36
GIPR P48546 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.35
LMNA P02545 2/20 0.35
KDM4E B2RXH2 1/20 0.35
HTT P42858 1/20 0.35
SMO Q99835 2/20 0.34
HPGD P15428 1/20 0.34
LIPE Q05469 3/20 0.34
PPARD Q03181 2/20 0.34
PPARA Q07869 2/20 0.34
ALDH1A1 P00352 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
PPARG P37231 1/20 0.34
S100A4 P26447 1/20 0.34
PTGES O14684 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6035190 0.92 GCGR (0.35) PTGDR2GCGRGIPRLMNAKDM4E
SCHEMBL6035906 0.91 HCRTR1 (0.40) PTGDR2GCGRGIPRSMN1; SMN2LMNA
SCHEMBL6035724 0.90 PPARD (0.40) PTGDR2SMN1; SMN2LMNAKDM4EHPGD
SCHEMBL6035938 0.88 PPARG (0.39) PTGDR2GCGRGIPRSMN1; SMN2LMNA
SCHEMBL6035417 0.85 SMN1; SMN2 (0.36) GCGRSMN1; SMN2LMNAKDM4EHTT
SCHEMBL6036258 0.85 SMN1; SMN2 (0.37) GCGRSMN1; SMN2LMNAKDM4EHTT
SCHEMBL6034602 0.85 PTGDR2 (0.38) PTGDR2GCGRGIPRSMN1; SMN2LMNA
SCHEMBL6035942 0.84 PTGDR2 (0.36) PTGDR2GCGRGIPRSMN1; SMN2LMNA
SCHEMBL6034691 0.83 SMN1; SMN2 (0.36) GCGRSMN1; SMN2LMNAKDM4EHTT
SCHEMBL6035913 0.82 SMN1; SMN2 (0.35) GCGRSMN1; SMN2LMNAKDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 PTGDR2 4688/4885GCGR 93/4885GIPR 194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.